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I . INTRODUCTION: REDUNDANCY O F MEDIATOR SYSTEMS 
In previous Chapters of this book, the involvement of various mediator systems i n 
allergic inflammation has been described. This Chapter focuses on the interdependence o f 
cell and mediator systems induced either by mechanical in jury, infectious diseases, noxious 
agents or, last but not least, allergic reactions. I n dependency on the intensity of the noxious 
event, a series of complex cellular and biochemical events, the so-called inflammatory 
response, w i l l occur in tissues. 
The inflammatory response constitutes a defense mechanism of the organism by which 
the stimulating agent or irritant is simultaneously eliminated and the healing process started 
to re-establish its integrity. The accompanying clinical symptoms of redness (rubor), swelling 
(tumor), heat (calor) and pain (dolor) have not lost any of their importance since their first 
presentation by the Roman physician Celsus (1st century A . D . ) . 
Our perception and knowledge of the biochemical and cellular reactions underlying 
inflammatory processes are changing continuously as a result o f ever improving techniques 
of investigations. The importance of known inflammatory mediators becomes relative as 
new factors are discovered, defined, and to date unknown interactions postulated. 
A n almost indefinite number of stimulators, mediators, effectors and inhibitors deter-
mines the efficiency or the failure of the inflammatory response. Taking a closer look at 
the pathomechanisms of inflammation, a redundancy becomes evident: Many cellular and 
humoral mediators cause the same or similar symptoms, and different cell types, e .g. , the 
phagocytes, are at least partially able to replace each other in function. Obviously, the 
inflammatory reaction is too important a protective mechanism to be seriously impaired by 
the loss of a single cell type or mediator. 
I I . G E N E R A L PATHOMECHANISMS 
Injuries caused by direct force or microtrauma due to muscular and skeletal strain lead 
to bleeding and a subsequent f ibr in deposit. The primary stimulus for the activation o f 
thrombocytes and the plasma enzyme cascade systems (coagulation, f ibrinolysis , comple-
ment, kal l ikrein-kinin system) is the exposure of surfaces normally inaccessible to the 
bloodstream (e.g. , subendothelial layer) to plasma constituents including cells (Figure 1) as 
well as the release of cellular factors including proteases. This initiates the inflammatory 
process. 
Local inflammation can be induced by physical means (e .g. , impaired tissue through 
straining, heat, cold, radiation, chemical substances), auto-immune processes and invasive 
microorganisms (bacteria, f u n g i , viruses). In response to the inflammatory s t imul i , the 
defense and eliminating mechanisms are primari ly cellular in nature wi th the phagocytes 
playing a major role. Vasoactive and permeability enhancing factors are released provoking 
the extravasation of f l u i d f rom the vasculature. This results in edema formation and thus 
swelling of the interstitial tissue. The impaired microcirculation leads to ischemia and hy-
poxia. 
During both injury and inflammation the biochemical, cellular, and immunological 
reactions all take the same course but with different emphasis being placed on each event 
according to the triggering st imuli . 
Attracted by chemotactic substances f rom the wounded or inflamed area, mobile leu-
kocytes adhere to the endothelium of capillary vessels and migrate into the altered tissue 
fo l lowing the concentration gradient o f the attracting substances. The polymorphonuclear 
granulocytes, which are the first to migrate (within hours after damage), are fol lowed by 
monocytes and macrophages (within 24 h) and somewhat later by eosinophils and lympho-
cytes (after a few days). It is the main task of these cells to eliminate degenerated and 
483 
injury — - Inflammation Infection 
Activation -
Humoral Systems 
& Mediators 
Τ 
Coagulation Cascade (SFMC) 
Fibrinolysis Cascade (FDP) 
Complement Cascade (C3a.C5a) 
Kallikrein-Kinin- System (Kinins) 
Cascade Proteinases 
Peptide Mediators (see f ) 
Mutual 
Activation 
Cellular Systems 
& Mediators 
τ 
Thrombocytes. Endothelial Cells 
Phagocytes (Granulocytes. 
Monocytes. Macrophages) 
Fibroblasts, Mast Cells, etc. 
Cellular Proteinases & Components 
Altered Structural Components 
FIGURE 1. Relationships between mediator systems, the plasma protease cascades and inflammatory 
cells, in inflammation, cf. Figure 2 and text. SFMC: soluble fibrin monomer complexes; FDP: fibrin or 
fibrinogen degradation products; C3a & C5a: complement-derived anaphylatoxins; Kinins, bradykinin, etc. 
impaired or destroyed tissue as wel l as foreign bodies and invasive microorganisms. I n order 
to be recognized and incorporated by the phagocytes the tissue particles or microbes have 
to be labeled ( 4 'opsonized") as being " f o r e i g n or degenerated" by humoral factors, the so-
called opsonins (e .g . , f ibronectin, immunoglobulins). After incorporation into phagosomes 
which fuse w i t h lysosomes to digestive vacuoles, the phagolysosomes, degradation of the 
intracellularly deposited material by hydrolytic and oxidative processes takes place. 
The immune system normally reacts more slowly than the non-specific defense mech­
anisms. Therefore, the specific recognition of foreign substances and invasive microorga­
nisms via antibodies or via cytotoxic T-lymphocytes usually takes place only days after the 
injury. Repair mechanisms responsible for the healing process start relatively early w i t h the 
proliferation of tissue-specific cells l ike histiocytes and fibroblasts. The stimulation of these 
cells by inflammatory mediators leads to the enhanced synthesis of tissue-specific substances 
such as collagen, elastin, and proteoglycans. 
The most important aspect of the inflammatory reaction is the close cooperation between 
the humoral and cellular systems (Figure 1). Thereby a decisive role is played by proteolytic 
enzymes (proteases or proteinases) and the products of system-specific proteolysis in the 
humoral enzyme cascade systems on the one hand and of non-specific proteolysis caused 
by liberated lysosomal enzymes on the other hand. Both the proteases themselves and 
products of their actions, the biologically highly active polypeptides, are potent inflammatory 
mediators. Their pathogenetic potential becomes relevant when the extent o f their production 
exceeds the requirement for the healing process. 
The system-specific proteases of the plasma enzyme cascades are generated f rom their 
inactive precursors (proenzymes) after direct (Hageman factor) or cofactor-transmitted con­
tact (high molecular weight kininogen for plasma prokall ikrein and factor X I ) w i t h wounded 
surfaces as wel l as by cellular proteases, e .g. , thrombokinases and plasminogen activators, 
that are released from altered or stimulated cells in the injured region. Their primary tasks 
are prevention of bleeding and induction of wound healing. Thrombin provokes f ibr in 
production and aggregation of thrombocytes. Plasmin digests the f ibr in during assembly of 
the repair tissue substances newly synthesized by fibroblasts. These cells are stimulated to 
produce repair tissue substances such as collagens, elastin, proteoglycans etc. by the f i b r i n -
stabilizing factor X I I I , which itself is activated by thrombin. Addit ional ly , several system-
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FIGURE 2. Pathomechanisms in inflammation: products of plasma proteinase cascade systems and phag-
ocytic processes as inflammatory mediators and their natural antagonists, proteinase inhibitors and antiox-
idants. For abbreviations see Figure 1 and text. 
specific proteases produce special inflammatory mediators (Figure 2): thrombin the soluble 
f ibr in monomer complexes (SFMC), plasmin the f ibr in and fibrinogen degradation products 
(FDP), the complement esterases via the classical ( C I esterases) and/or the alternative 
pathway (complement factor C3) the anaphylatoxins C3a, C4a, and C5a, and plasma ka l -
l ikrein the kinins. These peptide mediators are pathophysiologically active in several ways, 
for example, by: 
• Inhibit ion of coagulation (SFMC, FDP) 
• Increase in vasoactivity and reduction of blood pressure (anaphylatoxins and kinins) 
• Edema formation (FDP, anaphylatoxins and kinins) 
• Chemotaxis of granulocytes and monocytes (C5a and C3a) 
• Aggregation of thrombocytes and granulocytes (C5a) 
• Phagocytosis of granulocytes (C5a) 
• Degranulation (release of histamine) of mast cells (anaphylatoxins) 
I I I . C E L L U L A R SYSTEMS AND T H E I R MEDIATORS 
The cellular reactions which are initiated by the peptide mediators are transmitted either 
directly via mediator-specific receptors on the membranes of the target cells, or indirectly 
by stimulation of the synthesis of cellular mediators such as prostaglandins, leukotrienes 
etc. (Table 1). Kinins for instance have specific receptors on certain cells. Additionally they 
activate the ubiquitously occurring membrane-bound phospholipase A 2 which in turn initiates 
the synthesis of arachidonic acid metabolites. Depending on the actual k inin concentration 
and cell type, antagonistic prostaglandins (e.g. PGE 2 and PGF 2 a ) can also be produced during 
such a process. The diverse arachidonic acid metabolites activate particular functions o f 
their target cells (Table 1) which may either amplify or suppress the effect of the peptide 
mediators. These mechanisms operate to enhance or suppress the defense mechanism. 
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T A B L E 1 
Arachidonic Acid Metabolism in Inflammation: Stimulation and Metabolites 
(Eicosanoids) 
Stimuli 
ι 
Cell membrane 
I 
Release of: 
Proteinases, peptide mediators, hypoxia, toxins 
Phospholipase activation 
Arachidonic acid 
Enzymes produce: Cyclooxygenase or lipoxygenases etc. Prostaglandins (PG) & thromboxane (TX) or leu-
kotrienes & HPETEs & HETEs3 
Biological effects: Vasoconstriction: T X A 2 , PGF 2 o , PGD 2 , PGE2; LTC 4 , L T D 6 , LTE 4 ; HPETEs, HETEs 
vasodilation: PGE2, PGI 2 ; HPETEs, HETEs permeability increase: LTC 4 , L T D 4 , LTE 4 
platelet aggregation: T X A 2 , PGE2 platelet aggregation inhibition: PGI 2 , PGD 2 , PGE2 
neutrophil aggregation: LTB 4 ; HPETEs, HETEs 
Derivatives of hydroxyperoxy- or hydroxyeicosatetraenoic acid. 
T A B L E 2 
Cellular Mediators in Inflammation and Their Major Sources 
Mediator 
Histamine, Serotonine 
Platelet activating factor (PAF) 
Cytokines 
Interleukins ( I L 1 , 2, 3) 
GMCSF 2 b 
B-cell stimulating factor (BSF) 
Interferon-α,7 
Tumor necrosis factor (TNF) 
Arachidonic acid metabolites 
Prostaglandin E 2 (PGE2) 
Prostacyclin (PGI2) 
Thromboxane (TXA 2 ) 
Leukotriene B 4 (LTB 4 ) 
Leukotriene C 4 , D 4 , E 4 (SRSA)C 
Lysosomal proteinases (cf. Table 4) 
Lysosomal Glycosidases (cf. Table 4) 
Oxidants (reactive oxygen metabolites) 
Sourcea 
Bas, Mast, Thromb 
Bas, Mast, PMN 
Lympho, Macro 
Lympho 
Lympho 
Lympho, Macro 
Macro, Mono 
Macro, Mono, PMN 
Eos 
Macro, Thromb, PMN 
Bas, Mast, PMN 
Bas, Eos, PMN 
Macro, Mast 
Fibro, Macro, Mono, PMN 
Fibro, Macro, Mono, PMN 
Macro, Mono, PMN 
a Basophils; Lymphocytes; PMN = Neutrophils; Eosinophils; Macrophages; Mast cells; Fibroblasts; Monocytes; 
Thrombocytes 
b Granulocyte-monocyte colony stimulating factor. 
c Slow-reacting substances of anaphylaxis. 
In most cases the different defense or inflammatory cells produce several mediators. 
Some of the most potent ones, like the cytokines (Table 2) , have been characterized in 
greater detail only recently. They represent polypeptides or glycoproteins which can stimulate 
diverse functions of different target cells: Interleukins stimulate the growth of various cell 
populations ( IL1 and I L 2 of B- and T-lymphocytes and IL3 (like GMCSF) of hemopoetic 
stem cells of granulocytes, monocytes and eosinophils) as wel l as the synthesis of acute-
phase proteins ( IL1) . Addit ional ly , BSF promotes the growth of mast cells. The interferons 
α and y can activate monocytes and the immune defense when present in higher concen­
tration, whereas lower amounts suppress these functions. According to recent findings the 
tumor necrosis factor (TNF) is especially pathogenically effective: Among other effects it 
induces fever and activates adipocytes to l ipolysis, fibroblasts to synthesize PGE 2 and mast 
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cells to produce or liberate PAF, SRSA, histamine and serotonin (Table 2). Addit ional ly , 
T N F can stimulate granulocytes to such an extent that they excrete their lysosomal granules 
into the extracellular lumen which strongly promotes the inflammatory process. 
The described inflammatory mediators represent a most complex communication system 
whose most important function is to bring messages to cells. The messenger substances 
(mediators) can originate f rom the proteolytic cascade systems (coagulation, complement, 
kal l ikrein-kinin system etc.) and f rom cells. They can stimulate diverse cell populations and 
thus at the same time initiate different cell functions and may in some cases also activate 
the cells which produce them itself. On demand, they stimulate and enhance mediator 
production and thus an amplification of cell functions. A n important characteristic o f the 
cellular mediators is their restricted range and short l ifetime: They are rapidly bound and 
degraded by their target cells. Generally, higher mediator concentrations are found i n the 
inflamed area and its close surrounding as wel l as occasionally in the inflammatory exudates. 
Systemically, they can only be demonstrated (e .g . , in blood) for short periods during massive 
injuries or inflammatory processes. W i t h few exceptions, this also applies to the mediators 
originating f rom the proteolytic cascade systems like the kinins and anaphylatoxins. 
The regeneration capability of the organism relies on the fact that different mediators 
can initiate the same cell function. The healing process caused by essential cell functions 
is thus guaranteed even though one mediator is not produced in sufficient amounts. 
This communication system of the inflammatory mediators operating essentially for 
" impairment restr ict ion" and rapid healing implies, therefore, the interaction of agonistic 
and antagonistic stimulation on a cellular level. The organism can thus appropriately respond 
to the manifold traumatic and inflammatory st imuli to regain the balance of the disturbed 
physiological homeostasis. This aim is supported by an increased production of the so-called 
acute-phase proteins such as f ibrinogen, complement factor C3, C-reactive protein and 
ceruloplasmin which support the specific as wel l as the non-specific defense reactions. 
IV. PROTEINASE INHIBITORS 
Regulation of the proteinase activities o f the plasma cascade systems occurs by activation 
of inactive proenzymes via liberated cellular proteinases (e .g. , by thrombokinase and plas-
minogen activators) as wel l as by exposure of proenzymes and assembling factors to " f o r -
e i g n " , e .g. , subendothelial surfaces (intrinsic coagulation cascade). These processes which 
are essential for wound healing are primarily restricted to the injured area. The system-
specific proteinase inhibitors, antithrombin I I I , a 2 -plasmin inhibitor and Cl- inactivator pre-
vent excessive, i .e. systemic activation of the proteolytic cascades and thus simultaneously 
the formation of peptide mediators as wel l as non-specific proteolysis of endogenous proteins 
for example by plasmin (see Figure 2). In plasma these inhibitors are normally present in 
high excess over the maximally releasable amounts of their target enzymes. Thus they 
effectively restrict the activities of their primary target enzymes, thrombin (antithrombin 
I I I ) , plasmin (a 2 -plasmin inhibi tor) , complement CI-esterase and plasma kall ikrein ( C l -
inhibitor) . 
The outstanding characteristic of the proteinase inhibitors as protective substances against 
excessive proteolysis in the organism may be derived also from the fact that they represent 
the third largest plasma protein fraction besides albumin and the immunoglobulins. The 
primary target enzymes of most o f these inhibitors (approximately 90% of all of them) are 
the cellular proteinases and in particular the lysosomal digestive enzymes f rom phagocytes. 
It is the central task of the lysosomes containing phagocytes like granulocytes, monocytes 
and macrophages to l imi t the inflammatory process in the wound or inflamed area by 
phagocytosis of the inflammatory st imuli ( c f Chapter 52, Section I I ) . During the phagocytic 
process various aggressive substances which arise f rom the intracellular oxidation/degra-
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T A B L E 3 
Substrates of Lysosomal Proteinases from Phagocytes 
Connective tissue: 
elastin, collagen, proteoglycans, glycosaminoglycans, fibronectin, laminin, etc. 
Muscle proteins: 
myosin, tropomyosin, actin, troponin 
Opsonins: 
fibronectin, immunoglobulins, factors of the complement system, C-reactive protein, etc. 
Transport proteins: 
prealbumin, transferrin, haptoglobin, coeruloplasmin, etc. 
Proteinase inhibitors: 
a,-Proteinase inhibitor (α,-antitrypsin), α,-antichymotrypsin, antithrombin I I I , a2-plasmin inhibitor, Cl-inactivator 
Proteohormones: 
insulin, glucagon, substance P, kinins, etc. 
Receptors: 
insulin receptor on cell membranes 
T A B L E 4 
Lysosomal Digestive Enzymes 
Neutral serine proteinases (elastase, cathepsin G) 
Acid thiol and aspartate proteinases (cathepsins) 
Neutral metallo proteinases (collagenases) 
Aminopeptidases and carboxypeptidases 
Carbohydrate cleaving enzymes such as α-glucosidase, a-N-acetylglucosaminidase, α-glucoronidase, a-galacto-
sidase, α-mannosidase and lysozyme 
Phosphatases and phosphoprotein-phosphatases 
Arylsulfatases 
Phospholipases, lipases, triglyceride lipases 
Ribonucleases and desoxyribonucleases 
Myeloperoxidase (oxidizing in the presence of hydrogen peroxide: H 2 0 2 ) 
dation machinery are released from the cell . However, they are normally rapidly inactived 
by specific antagonists. Those include α j-proteinase inhibitor, which is present in high 
concentration in interstitial f l u i d , as wel l as antioxidants such as superoxide dismutase (SOD) 
and catalase being of cellular or igin. After immigration of the phagocytes into the inflamed 
area, their overstimulation, for instance by T N F or larger amounts of C3a, can cause 
degranulation. In this process the lysosomal granules are excreted and their content is thus 
released extracellularly which may result in a local exhaustion of the endogenous protective 
antagonists. By this means the most important inhibitor o f the lysosomal proteinase elastase 
from granulocytes, a r proteinase inhibitor, is inactivated both oxidatively by the myelo-
peroxidase/hydrogen peroxide system or oxygen free radicals, and proteolytically by catheptic 
thiol proteinases and neutral metallo proteinases f rom macrophages. The lysosomal elastase, 
which is produced in an amount of approximately 300 mg/d has its optimum proteolytic 
activity in the physiological p H range and can therefore unrestrictedly degrade structural 
elements such as basal membranes, elastin, collagen, fibronectin, and proteoglycans as wel l 
as humoral factors including the proteinase inhibitors o f the plasma cascade systems (see 
Figure 2 and Table 3). This degradation process is strongly enhanced by various other 
hydrolytic enzymes derived f rom degranulated and disintegrated phagocytes and tissue cells 
in the inflamed area (see Table 4) . The released lysosomal proteinases exhibit strongest 
pathogenetic effects (cf. Figure 2 and Table 3). Hence, the tools o f the intracellular protein 
catabolism become extracellularly potent inflammatory mediators through the fo l lowing 
mechanisms: 
1 the destruction of vital endogenous structural and humoral substances leading among 
others to 
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2. severe alterations of tissues and thus to the exposure of normally coated structures as 
" f o r e i g n surfaces" which stimulate the immunological defense mechanisms; this may 
result in chronic inflammation or in an autoimmune disease; 
3. the production of other inflammatory mediators in a direct or indirect way. For instance, 
lysosomal elastase can cleave o f f a C3a-like anaphylatoxin from complement factor 
C3, but can also provoke an increased production of peptide mediators of the plasma 
enzyme cascade systems by proteolytic inactivation of relevant proteinase inhibitors 
(see Figure 2 and Table 3). 
In this way an init ial ly local tissue defect or inflammatory process is spread by various 
transport media (interstitial f l u i d , lymph f l u i d , blood): the body temperature rises, the gran­
ulocytes are mobilised, and the synthesis o f non-specific defense proteins, the acute-phase 
reactants, is stimulated. 
Remarkably, the protective or regulatory proteinase inhibitors, α,-proteinase inhibitor, 
CI - inh ib i tor , and a^antichymotrypsin, are also acute-phase reactants. The latter responds 
especially quickly (wi th in a few hours) and strongly (increase in concentration up to six 
times of the normal level in plasma) due to an inflammatory stimulus. I t seems logical that 
the organism reacts to an increased requirement of protective substances during the inf lam­
matory process w i t h an enhanced synthesis especially of a 1 -antichymotrypsin and a t -pro ­
teinase inhibitor, the inhibitors of lysosomal digestive proteinases. The importance of such 
a counter-regulation for the healing process is underlined by the observation that the excessive 
consumption of proteinase inhibitors such as antithrombin I I I and a 2 -macroglobulin, which 
are not acute-phase proteins, has a very bad prognosis. a 2 -Macroglobul in very effectively 
inhibits most of the lysosomal proteinases as wel l as plasmin and plasma kal l ikrein . 
Proteolytic processes are principally irreversible and often destructive. Therefore, an 
increased turn-over or metabolization rate of endogenous substances (for instance after tissue 
injuries) has to be balanced by de novo synthesis o f relevant substances or tissues which 
proceeds only s lowly. This is in clear contrast to the possibility of an immediate counter-
regulation w i t h other inflammatory systems comprising for example the arachidonic acid 
metabolites (prostaglandins, leukotrienes etc.) and biogenic amines, whereby antagonistically 
effective mediators can be produced and released most rapidly. 
V, DIAGNOSTIC APPROACHES TO INFLAMMATORY 
PROCESSES 
A t present, a clearcut chemical diagnosis of locally restricted inflammatory processes 
is not possible systemically. The quantities o f inflammatory mediators present outside the 
inflamed area are minute as they are rapidly metabolized and eliminated. Moreover, they 
have only a short l ife-time and thus a l imited range of action. However, they may be detected 
in inflammatory effusions, a fact, that has significantly contributed to the elucidation of 
locally proceeding pathomechanisms. A more favorable situation exists when characteristic 
metabolites accumulate and become detectable through sensitive and specific immunological 
methods. This is true for certain arachidonic acid metabolites and the lysosomal elastase 
from granulocytes. Elastase normally is present in blood as enzyme-α,-proteinase inhibitor 
complex, i . e . , i n an enzymatically inactive f o r m . This complex is eliminated f rom the cir­
culation via the reticuloendothelial system (RES) with a half-l ife of approximately 1 h (cf. 
Figure 2). 
Cell-specific factors of this type are gaining importance for diagnostic purposes and 
their release pattern during the inflammatory reaction may give valuable hints for new 
therapeutic approaches. 
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V I . MEDICINAL T H E R A P Y CONCEPTS 
Drug-related therapy concepts for the treatment of inflammatory processes should be 
orientated primari ly on the extent o f participation and the mode of action of inflammatory 
mediators and cells and the cascade systems as w e l l . This especially applies to the corti-
costeroids which — as we know today — diversely influence the various cellular systems. 
For example, as membrane 1/2 protecting agents they inhibit the synthesis of prostaglandins 
and leukotrienes thereby diminishing protein exudation into the interstitial space and thus 
reducing edema formation. On the other hand, corticosteroids suppress the phagocytic po-
tential of inflammatory cells, especially that of the granulocytes. Thereby the capability of 
these cells to clear damaged tissue, toxic metabolites and invasive microorganisms is sig-
nificantly reduced. However, the clearance function is essential for the healing process. In 
addition, the corticosteroids impair the immune defense thus making the organism sensitive 
to bacterial and other infections. Even the plasma cascade systems are influenced by cor-
ticosteroids, e .g . , by stimulation or inhibit ion of the synthesis of plasminogen activators 
and their inhibitors. This diversity of actions makes the therapeutic use of corticosteroids 
in inflammatory diseases rather problematic, especially i f such a therapy is performed w i t h 
high doses over a longer period. There is danger then that for short-term, positive effects 
extensive disadvantages have to be put up w i t h regard to long-term wound healing and 
defense against infections. 
Today's attention is directed towards the development of nonsteroidal anti-inflammatory 
drugs (NSAIDs) . In experimental models and clinical studies, a number of such drugs are 
being currently tested for their compatability and therapeutic usefulness. NSAIDs are mostly 
substances which inhibit the synthesis of cellular mediators and certain cell functions (cf. 
Table 1 and 2). Inhibit ion of cell functions can be achieved by the blockade of mediator-
specific receptors by mediator antagonists. The best results so far have been achieved by 
selectively acting inhibitors and antagonists. Examples are the inhibit ion of leukotriene 
synthesis or phagocyte stimulation by T N F . In the clinical application of NSAIDs one has 
to be aware of the fact that a close cooperation of inflammatory mediators and inflammatory 
cells is essential for the healing process. Drugs should control excessive production and 
stimulation to such a degree that physiological levels are maintained. Drug treatment should 
especially avoid impairment of the phagocytic process including the clearance function and 
the immunological defense reactions. 
Compared to the application of N S A I D s , therapeutic approaches to avoid overactivation 
of proteolytic cascade systems on the one hand and the extracellular oxidative denaturation 
and proteolytic digestion on the other hand are wel l understood. It is possible to measure 
endogenous inhibitor levels of lysosomal digestive enzymes quickly and reliably. The dosage 
and the therapeutically effective concentration of administered proteinase inhibitors are easy 
to regulate in vivo. When unequivocal indications such as congenital or acquired massive 
inhibitor deficiency syndromes exist, protein-inhibitors are already applied cl inically. Ex-
amples include a,-proteinase inhibitor (as an inhibitor of granulocytic elastase) for treatment 
of lung emphysema, antithrombin I I I for treatment of life-threatening coagulation defects, 
and the C1 -esterase inhibitor (C1 -inactivator) for the treatment of angioneurotic edema (see 
Figure 2). Various laboratories are currently producing proteinase inhibitors by recombinant 
D N A techniques for therapeutic purposes. Those include the abovementioned inhibitors as 
well as other human proteinase inhibitors of thrombin (e.g. hirudin) and of the granulocytic 
elastase (e.g. variants of a r proteinase inhibitor and the miniprotein eglin). I f the application 
of inhibitors in severe diseases such as sepsis, polytrauma and acute respiratory distress 
syndrome (ARDS) show the expected positive results, their more general therapeutic use 
for wound healing and local inflammatory processes should be envisaged. 
The theoretical basis for the therapeutic application of antioxidants is based on the same 
490 Late Phase Allergic Reactions 
Stimuli 
- I I 
Chemoattractants 
Reactive 
Oxygen Metabolites 
^ - - - 0 2 . H 2 ° 2 
1 1 0 2 , OH 
Elastase Myeloperoxidase Lactoferrin 
' Eglin 
Ε - I — Fl 
H2O2/ \H2O2, 02 
\ 
—ί-Λ Catalase 
/ | 2 H ? 0 , ^ 0 , · 2 H :,0( \ 
SOD I 
2 0} - P H ' - O . . * Η,Ο,Γ 
Unspeclfic 
Proteolysis 
V.il 4 X 
M e t i-X 
Oxidative 
Denaturation 
H-,0- + CI .°Η;Ό •· OCI 
H . Ü , I OCI - H;;0 f CI ••- Ό , 
Multifunctional: 
Oxid. Denaturation 
Op + Fe-'' ··- Fe?' » 0;. 
H:.02 · Fe:'! - - F e 3 ' t OH t OH 
Iron Transport 
Complement Inhibition etc 
FIGURE 3. Lysosomal factors and products of phagocytic processes 
released extracellularly due to overstimulation of polymorphonuclear gran­
ulocytes (PMN) and suitable antagonists for their elimination. 
basic principles and is similarly wel l defined as in the case of the proteinase inhibitors (see 
Figures 2 and 3). A n optimal substance would be one which rapidly eliminates accumulating 
oxidants in the extracellular space. Superoxide dismutase (SOD), which is already applied 
in special clinical situations, converts the relatively short-living superoxide radicals ( 0 2 ~ ) 
to hydrogen peroxide ( H 2 0 2 ) . However hydrogen peroxide also acts — together w i t h mye­
loperoxidase — as a strong oxidant and rapidly inactivates, among others, the α prote inase 
inhibitor. Thus, the simultanous application of an agent such as catalase which eliminates 
H 2 0 2 is necessary. On a long-term basis, a better solution is the development of low molecular 
mass synthetic antioxidants which have a broad scavanger spectrum and can be given orally. 
Intensive research in this area makes it l ikely that the therapy of inflammatory processes 
can be much improved by the application of N S A I D as wel l as by proteinase inhibitors and 
antioxidants in the future. 
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